[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pulse Biosciences CS (PLSE)

Pulse Biosciences CS (PLSE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,301,733
  • Shares Outstanding, K 68,225
  • Annual Sales, $ 350 K
  • Annual Income, $ -72,780 K
  • EBIT $ -59 M
  • EBITDA $ -76 M
  • 60-Month Beta 1.63
  • Price/Sales 3,719.24
  • Price/Cash Flow N/A
  • Price/Book 16.05

Options Overview Details

View History
  • Implied Volatility 91.32% (-28.25%)
  • Historical Volatility 100.56%
  • IV Percentile 4%
  • IV Rank 3.47%
  • IV High 352.51% on 11/20/25
  • IV Low 81.93% on 04/17/26
  • Expected Move (DTE 2) 0.00 (0.00%)
  • Put/Call Vol Ratio 3.08
  • Today's Volume 49
  • Volume Avg (30-Day) 29
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 1,241
  • Open Int (30-Day) 1,350
  • Expected Range 23.30 to 23.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.31
  • Number of Estimates 1
  • High Estimate $-0.31
  • Low Estimate $-0.31
  • Prior Year $-0.28
  • Growth Rate Est. (year over year) -10.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.22 +27.88%
on 04/13/26
24.84 -6.20%
on 04/22/26
+4.63 (+24.80%)
since 04/10/26
3-Month
17.46 +33.45%
on 03/03/26
25.80 -9.69%
on 02/18/26
-0.10 (-0.43%)
since 02/12/26
52-Week
12.56 +85.51%
on 11/20/25
26.30 -11.41%
on 02/11/26
+6.51 (+38.77%)
since 05/12/25

Most Recent Stories

More News
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulseâ„¢ technology using proprietary nanosecond pulsed field ablation (nsPFAâ„¢) energy, today announced its Co-Chairmen of the Board, Robert Duggan...

PLSE : 23.30 (+22.12%)
Pulse Biosciences Q1 Earnings Call Highlights

Pulse Biosciences (NASDAQ:PLSE) said it is sharpening its focus on its nanosecond pulsed field ablation platform for atrial fibrillation after reporting first-quarter 2026 results and highlighting new...

PLSE : 23.30 (+22.12%)
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulseâ„¢ technology using proprietary nanosecond pulsed field ablation (nsPFAâ„¢) energy, today announced plans to participate in the upcoming BofA...

PLSE : 23.30 (+22.12%)
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

Accelerates Enrollment Timeline for the Cardiac Catheter IDE Conference Call to Be Held Thursday, May 7th to Discuss Business Updates and Financial Results...

PLSE : 23.30 (+22.12%)
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulseâ„¢ Cardiac Catheter System at Heart Rhythm 2026

Multicenter results show sustained high durability and procedural efficiency, redefining positive expectations for catheter ablation in patients with atrial fibrillation

PLSE : 23.30 (+22.12%)
Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting

nPulseâ„¢ Technology highlighted in late-breaking feasibility study and live case transmission

PLSE : 23.30 (+22.12%)
Pulse Biosciences to Host Analyst Event on April 25, 2026

Management to discuss late-breaking data and the clinical program for its nPulse Cardiac Catheter System

PLSE : 23.30 (+22.12%)
Pulse Biosciences Strengthens Executive Leadership Team

Appoints Liane Teplitsky as Chief Operating Officer Expands Dr. David Kenigsberg’s Chief Medical Officer Role

PLSE : 23.30 (+22.12%)
Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulseâ„¢ Cardiac Catheter System for Atrial Fibrillation

U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study

PLSE : 23.30 (+22.12%)
Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference

Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulseâ„¢ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFAâ„¢), today announced plans to present at the upcoming 25 ...

PLSE : 23.30 (+22.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Pulse Biosciences, Inc. is a medical device company. It is engaged in developing a novel and proprietary tissue treatment platform using Nano-Pulse Electro-Signaling. NPES provide effective local tumor control and to initiate an adaptive immune response. The company deploy NPES platform applications...

See More

Key Turning Points

3rd Resistance Point 26.96
2nd Resistance Point 25.21
1st Resistance Point 24.25
Last Price 23.30
1st Support Level 21.54
2nd Support Level 19.79
3rd Support Level 18.83

See More

52-Week High 26.30
Last Price 23.30
Fibonacci 61.8% 21.05
Fibonacci 50% 19.43
Fibonacci 38.2% 17.81
52-Week Low 12.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.